“After Shocks” with Milind Desai, MD, MBA, FACC, FAHA, FESC
NYACC is proud to present the next installment in its After Shocks series.
These sessions provide bite-sized recaps of high-impact lectures from prominent Cardiology conferences, such as those hosted by ACC, HRS, HFSA, AHA, SCAI and more.
Please join us for a discussion with Milind Desai, MD, MBA, FACC, FAHA, FESC, who will be discussing the VALOR-HCM trial findings and his associated paper, which will be published in JACC the same week.
The VALOR-HCM trial showed that mavacamten improved symptoms and significantly reduced eligibility for needing septal reduction therapy (SRT) among symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) who were considering SRT and on maximally tolerated medical therapy.
Speaker: Milind Desai, MD, MBA, FACC, FAHA, FESC / Director, Clinical Operations / Cleveland Clinic Heart, Vascular, and Thoracic Institute – Cleveland
Moderator: Srihari S. Naidu, MD, FACC, FAHA, FSCAI / President, NYACC / Director, Cardiac Catheterization Laboratory / Director, Hypertrophic Cardiomyopathy Center / Professor of Medicine, New York Medical College / Westchester Medical Center / WMCHealth Network
.
| What: | “After Shocks” with Milind Desai, MD, MBA, FACC, FAHA, FESC |
| When: | Wednesday, July 6th, 4 p.m. Eastern |
| Where: | Webinar |
| Cost: | Free |
| Registration: | Register here or by clicking the registration button above. |
| Additional Information: |
[email protected] | (212) 686-0228 |
Speaker – Milind Desai, MD, MBA, FACC, FAHA, FESC
